Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase

Gaucher disease (GD) is characterized by accumulation of glucosylceramide in lysosomes due to mutations in the GBA1 gene encoding the lysosomal hydrolase β-glucocerebrosidase (GCase). The disease has a broad spectrum of phenotypes, which were divided into three different Types; Type 1 GD is not associated with primary neurological disease while Types 2 and 3 are associated with central nervous system disease. GCase molecules are synthesized on endoplasmic reticulum (ER)-bound polyribosomes, translocated into the ER and following modifications and correct folding, shuttle to the lysosomes. Mutant GCase molecules, which fail to fold correctly, undergo ER associated degradation (ERAD) in the proteasomes, the degree of which is one of the factors that determine GD severity. Several pharmacological chaperones have already been shown to assist correct folding of mutant GCase molecules in the ER, thus facilitating their trafficking to the lysosomes. Ambroxol, a known expectorant, is one such chaperone. Here we show that ambroxol increases both the lysosomal fraction and the enzymatic activity of several mutant GCase variants in skin fibroblasts derived from Type 1 and Type 2 GD patients.

[1]  E. Beutler,et al.  Enzyme Replacement in Gaucher Disease , 2004, PLoS medicine.

[2]  A. Pisani,et al.  Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease , 2012, Journal of Inherited Metabolic Disease.

[3]  S. Chung,et al.  The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms , 2006, Proceedings of the National Academy of Sciences.

[4]  D. Lockhart,et al.  Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  S. Ishii,et al.  Hydrophilic iminosugar active‐site‐specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients , 2006, The FEBS journal.

[6]  M. Horowitz,et al.  ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. , 2007, Human molecular genetics.

[7]  D. Mahuran,et al.  Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. , 2009, Molecular genetics and metabolism.

[8]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Yoshitomo Hamuro,et al.  Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease* , 2009, The Journal of Biological Chemistry.

[10]  F. Platt,et al.  Substrate reduction therapy , 2008, Acta paediatrica.

[11]  Chi‐Huey Wong,et al.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. , 2007, Journal of medicinal chemistry.

[12]  R. Kopito.  ER Quality Control: The Cytoplasmic Connection , 1997, Cell.

[13]  Noel Southall,et al.  Non-iminosugar glucocerebrosidase small molecule chaperones. , 2012, MedChemComm.

[14]  G. Grabowski.  Phenotype, diagnosis, and treatment of Gaucher's disease , 2008, The Lancet.

[15]  R. Brady,et al.  The role of neurogenetics in Gaucher disease. , 1993, Archives of neurology.

[16]  M. Horowitz,et al.  Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. , 2011, Blood Cells, Molecules & Diseases.

[17]  P. Compain,et al.  Metal-free one-pot oxidative amidation of aldoses with functionalized amines. , 2008, The Journal of organic chemistry.

[18]  Yoshiyuki Suzuki,et al.  Conformationally-locked N-glycosides with selective β-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease. , 2012, Journal of medicinal chemistry.

[19]  E. Brown,et al.  Identification of Pharmacological Chaperones for Gaucher Disease and Characterization of Their Effects on β‐Glucocerebrosidase by Hydrogen/Deuterium Exchange Mass Spectrometry , 2008, Chembiochem : a European journal of chemical biology.

[20]  M. Horowitz,et al.  ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity , 2005 .

[21]  J. Bonifacino,et al.  Ubiquitin and the control of protein fate in the secretory and endocytic pathways. , 1998, Annual review of cell and developmental biology.

[22]  T. Butters,et al.  Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease. , 2012, Journal of medicinal chemistry.

[23]  A. Kermode,et al.  Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant. , 2012, Molecular genetics and metabolism.

[24]  M. Horowitz,et al.  Intracellular cholesterol modifies the ERAD of glucocerebrosidase in Gaucher disease patients. , 2008, Molecular genetics and metabolism.

[25]  T. Butters,et al.  Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease. , 2012, Organic & biomolecular chemistry.

[26]  J. M. Benito,et al.  Pharmacological chaperone therapy for Gaucher disease: a patent review , 2011, Expert opinion on therapeutic patents.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  D. Urban,et al.  N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. , 2007, Bioorganic & medicinal chemistry letters.

[29]  Ying Sun,et al.  Ex Vivo and in Vivo Effects of Isofagomine on Acid β-Glucosidase Variants and Substrate Levels in Gaucher Disease* , 2011, The Journal of Biological Chemistry.

[30]  Gregory A Petsko,et al.  Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. , 2006, Nature chemical biology.

[31]  Noel Southall,et al.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. , 2012, Journal of medicinal chemistry.

[32]  E. Lesellier,et al.  Second‐Generation Iminoxylitol‐Based Pharmacological Chaperones for the Treatment of Gaucher Disease , 2011, ChemMedChem.

[33]  R. Van Tiggelen,et al.  Gaucher disease , 2019, Haematology.

[34]  A. Zimran.  How I treat Gaucher disease. , 2011, Blood.

[35]  E. Beutler.  2 Gaucher Disease11This is manuscript 8587-MEM from The Scripps Research Institute. Supported by National Institutes of Health Grants DK36639 and RR00833 and the Sam Stein and Rose Stein Charitable Trust Fund. , 1995 .

[36]  J. Kelly,et al.  Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. , 2011, Biochemistry.

[37]  S. Withers,et al.  Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease. , 2012, Journal of medicinal chemistry.

[38]  Christopher P Austin,et al.  Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease , 2007, Proceedings of the National Academy of Sciences.

[39]  Yoshiyuki Suzuki,et al.  A Fluorescent sp2‐Iminosugar With Pharmacological Chaperone Activity for Gaucher Disease: Synthesis and Intracellular Distribution Studies , 2010, Chembiochem : a European journal of chemical biology.

[40]  Yoshiyuki Suzuki,et al.  The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice , 2013, Brain and Development.

[41]  Noel Southall,et al.  High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase , 2012, PloS one.